Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF)

NACompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 1, 2011

Primary Completion Date

April 16, 2015

Study Completion Date

April 16, 2015

Conditions
Cystic Fibrosis
Interventions
DIETARY_SUPPLEMENT

ECGC

1 cycle will comprise 28 days of continuous daily treatment with EGCG given once/day(total 375 mg) /day in the morning with food followed by a 14 day wash out period without drug.

DIETARY_SUPPLEMENT

Tocotrienol

One cycle will comprise 28 days of continuous daily treatment with Tocotrienol given 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.

DIETARY_SUPPLEMENT

EGCG + Tocotrienol

combination of both arms 375 mg EGCG + 600mg/day Tocotrienol

Trial Locations (1)

91240

Hadassah Medical Organization, Mount Scopus, Jerusalem

All Listed Sponsors
lead

Hadassah Medical Organization

OTHER

NCT00889434 - Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF) | Biotech Hunter | Biotech Hunter